Join

Compare · BDTX vs RVMD

BDTX vs RVMD

Side-by-side comparison of Black Diamond Therapeutics Inc. (BDTX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDTX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • RVMD is the larger of the two at $33.10B, about 276.4x BDTX ($119.8M).
  • Over the past year, BDTX is down 15.9% and RVMD is up 286.9% - RVMD leads by 302.8 points.
  • RVMD has been more active in the news (6 items in the past 4 weeks vs 4 for BDTX).
  • RVMD has more recent analyst coverage (25 ratings vs 13 for BDTX).
PerformanceBDTX-15.90%RVMD+286.88%
2025-06-05+0.00%2026-06-04
MetricBDTXRVMD
Company
Black Diamond Therapeutics Inc.
Revolution Medicines Inc.
Price
$2.09-0.48%
$155.45-0.38%
Market cap
$119.8M
$33.10B
1M return
-26.92%
+5.66%
1Y return
-15.90%
+286.88%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2020
2020
News (4w)
4
6
Recent ratings
13
25
BDTX

Black Diamond Therapeutics Inc.

Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

RVMD

Revolution Medicines Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.

Latest BDTX

Latest RVMD